At a median 5-year (60.3 months) planned follow-up of the Phase 2b KEYNOTE-942/mRNA-4157-P201 study, intismeran autogene in combination with KEYTRUDA demonstrated a 49% reduction in the risk of ...
Scale becomes manageable when generative AI is treated as a service with explicit constraints and measurable outcomes. Rely ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results